Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
316 daily bars · split adjusted
Current price $1.05
Latest analyst grade actions
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 37.54 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 5.88 | Oscillator | Buy |
| Williams %R (14) | -91.67 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.04 (Hist -0.02) | Oscillator | Strong Sell |
| Average Directional Index (14) | 11.62 (+DI 17.8 / -DI 17.1) | Trend | Neutral |
| EMA 20 | 1.18 | MA | Strong Sell |
| SMA 20 | 1.19 | MA | Strong Sell |
| EMA 50 | 1.24 | MA | Strong Sell |
| SMA 50 | 1.25 | MA | Strong Sell |
| SMA 200 | 1.14 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 6, 26 | Wilson Glynn | director, officer: Chief Executive Officer | A-Award | 75,000 @ $1.13 | $84.75K |
| Sep 28, 26 | Alila Hector W | director | A-Award | 50,000 @ $1.24 | $62.00K |
| Sep 28, 26 | Melton Christopher | director | A-Award | 50,000 @ $1.24 | $62.00K |
| Sep 28, 26 | Galeta Christopher Matthew | director | A-Award | 25,000 @ $1.24 | $31.00K |
| Sep 28, 26 | Meadows Brian | officer: Chief Financial Officer | A-Award | 25,000 @ $1.24 | $31.00K |
| Sep 4, 26 | Meadows Brian | director: | 0 | — | |
| Jul 23, 26 | John Brian | director, officer: Interim CFO | J-Other | 150,000 @ $1.00 | $150.0K |
TTM vs. 5-year historical average (annual ratios)
| Metric | CABR | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.4x | -1.9x · sector 20.7x | Discount |
| Forward P/E | — | — | n/a |
| Price / Book | 4.2x | 5.6x | Discount |
| Price / Sales | 8229.4x | 2760.6x | Elevated |
| EV / EBITDA | -1.8x | -1.8x | In line |
| Return on equity | -386.2% | — | Weak |
| Gross margin | 59.2% | 55.6% | In line |
| Debt / Equity | 0.00 | 0.03 | Conservative |
| Piotroski / Altman Z | —/9 | Z — | n/a |
Discounted cash flow model
Stock news · updated daily
According To Company's Recent 8K, The Company Initially Closed On $4.6 Million Of A $9.0 Million Round That Is In Progress On A Rolling Basis
Commercial Patent Portfolio Includes Five Issued U.S. Patents Protecting Core Flagship Platforms Targeting $20B+ Combined Global Dermatology & Hair Care Markets Fort Pierce, FL, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Caring Brands Inc. (Nasdaq: CABR) a wellness consumer-products company, today provided an update on its expanding intellectual property (IP) portfolio, which now includes five issued U.S. patents covering two of the Company's principal product platforms: Hair Enzyme Booster and Photocil. Four of the issued patents cover Hair Enzyme Booster, while the fifth supports Photocil.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | — | -0.10 | — | — |
| May 12, 2026 | — | -0.27 | — | — |
| Mar 31, 2026 | — | -0.29 | — | — |
| 4 | Sep 30, 2026 | 2026-09-30 06:14:48 | View |
| 4 | Sep 30, 2026 | 2026-09-30 06:11:00 | View |
| 8-K | Sep 22, 2026 | 2026-09-22 16:30:17 | View |
| 3 | Sep 17, 2026 | 2026-09-17 19:32:08 | View |
| 8-K | Sep 11, 2026 | 2026-09-11 14:46:01 | View |
| 8-K | Sep 10, 2026 | 2026-09-10 17:07:56 | View |
Proxy statement (DEF 14A) disclosures